FOXA vs LAB · P/E 14, $24.50B cap vs rev $174.4M
Fox Corp Class A (FOXA) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
FOXA does not have a complete income-statement cache yet.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
FOXA currently screens at market cap $24.50B and trailing P/E 14.1. LAB currently screens at market cap $317.1M.
Not investment advice. Open the FOXA and LAB stock pages for the full models.
Not investment advice.